Core Viewpoint - MaxCyte, Inc. has granted inducement awards to Parmeet Ahuja as part of his appointment as Chief Financial Officer, which includes stock options and restricted stock units (RSUs) [1] Group 1: Inducement Awards - The Compensation Committee granted stock options to purchase 375,000 shares and RSUs for 187,500 shares to Parmeet Ahuja [1] - The stock options have a ten-year term with an exercise price of $0.676, based on the closing price on March 30, 2026 [2] - The RSUs will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in three equal annual installments [3] Group 2: Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [4] - The company utilizes Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [4] - With over 25 years of experience, MaxCyte aims to shape the future of medicine by empowering researchers globally [4]

Core Insights - The involvement of CFOs in AI projects significantly enhances the value extracted from these initiatives, with 76% of companies achieving substantial value when CFOs are responsible for AI outcomes [1][3]. Group 1: CFOs and AI Value - Only 2% of surveyed executives indicated that CFOs are tasked with achieving value from AI, yet their involvement correlates with a much higher success rate in value realization [3]. - CFOs can develop methodologies for AI implementation and scale them across the organization, bringing institutional credibility to the metrics used [3]. Group 2: Case Studies and Economic Impact - At DBS Bank in Singapore, CFOs are responsible for validating AI value metrics, contributing to an estimated economic value generation of approximately 1 billion Singapore dollars from data analytics and AI initiatives [4]. Group 3: AI Types and Challenges - Generative AI is identified as the most challenging type to establish value from, with 44% of respondents citing difficulties, likely due to challenges in measuring productivity [5]. - Agentic AI and analytical AI follow in difficulty, with 24% and 16% respectively, while rule-based AI is the least difficult to measure [6]. Group 4: Recommendations for AI Implementation - It is advised to involve finance teams in tracking and aggregating metrics related to AI value, as this can lead to a 23-point advantage in achieving high value when both employees and leaders are trained in AI [7]. - Organizations are encouraged to adopt a "narrow and deep AI" approach, focusing on specific processes rather than merely integrating AI into existing workflows [9]. Group 5: Workforce Impact - Only 2% of organizations have made significant AI-driven headcount reductions, but nearly 90% have reduced or frozen hiring in anticipation of AI's impact [8].

Core Insights - MaxCyte, Inc. has launched ExPERT DTx™, a high throughput transfection platform aimed at enhancing research and drug discovery in cell therapeutics [1][4] Group 1: Product Features - ExPERT DTx can process up to 96 samples in a single three-minute run, making it one of the most efficient solutions for 96-well electroporation available [2] - The platform features a modular R-50x96™ well processing assembly that allows for parallel processing of 12 detachable 8-well strips with unique parameters for different cell and cargo combinations, ensuring consistent performance and reducing laboratory waste [2] - The DTx Software and DTx Designer software provide user-friendly controls and remote experiment design capabilities, maximizing instrument uptime and benefiting labs conducting multiple experiments [3] Group 2: Company Commitment - MaxCyte emphasizes its commitment to customer needs by developing ExPERT DTx to provide flexibility in research while ensuring reproducible results with high cell viability at an affordable price [4] - The company has over 25 years of experience in advancing cell engineering, focusing on the discovery, development, and commercialization of next-generation cell therapies [5]

Core Insights - MaxCyte, Inc. provided a preliminary update on its financial results for Q4 and the full year 2025, indicating a challenging yet productive year with core revenue in line with guidance [1][3] - The company reported total cash, cash equivalents, and investments of approximately $155.6 million as of December 31, 2025 [2] - Core revenue for Q4 is expected to be between $6.6 million and $6.7 million, while full-year core revenue is projected to be between $29.5 million and $29.6 million [5] - Strategic Platform License (SPL) program-related revenue for Q4 is expected to be between $0.4 million and $0.6 million, with full-year SPL revenue anticipated to be between $3.3 million and $3.5 million [5] Company Strategy and Outlook - The company aims to improve its cost structure and drive efficient growth towards profitability, entering 2026 with reduced annual burn and a leaner organization [3] - MaxCyte is optimistic about the opportunities presented by its SPLs and the expansion of its SeQure services, expecting a return to revenue growth in the second half of 2026 [3] - The company plans to launch new offerings early in 2026, indicating a focus on innovation and market expansion [3] Technology and Services - MaxCyte specializes in cell engineering, providing technologies that facilitate the discovery, development, and commercialization of next-generation cell therapies [4] - The company’s Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services are designed to enable precise and scalable cell engineering [4] - With over 25 years of experience, MaxCyte continues to advance cell engineering, contributing to the future of medicine [4]

Core Points - MaxCyte, Inc. announced that Chief Financial Officer Douglas Swirsky will transition from his role in the first half of 2026, with a structured search process initiated to find his successor [1][2] - Swirsky will remain in his position until a successor is appointed and will continue in an advisory role post-transition to support strategic initiatives [1][2] - The transition is not expected to impact the company's operations, financial reporting, or strategic priorities [2] Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3] - The company utilizes Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [3] - With over 25 years of experience, MaxCyte aims to empower researchers globally to develop safe and effective treatments for human health [3]

Core Insights - MaxCyte, Inc. reported a total revenue of $6.8 million for Q3 2025, a decrease of 16% compared to $8.2 million in Q3 2024 [5][6] - The company announced an operational restructuring aimed at reducing costs and accelerating profitability while maintaining long-term growth potential [3][6] - MaxCyte reiterated its 2025 revenue guidance, expecting total cash, cash equivalents, and investments to end the year between $152 million and $155 million [10][14] Financial Performance - Core business revenue for Q3 2025 was $6.4 million, down 21% from $8.1 million in Q3 2024 [7][8] - Gross profit for Q3 2025 was $5.2 million, reflecting a gross margin of 77%, compared to a gross margin of 76% in Q3 2024 [8][9] - The net loss for Q3 2025 was $12.4 million, compared to a net loss of $11.6 million in the same period of 2024 [9][26] Revenue Breakdown - Revenue from instruments was $1.4 million, down 22% from $1.8 million in Q3 2024 [4] - Revenue from PAs and consumables decreased by 25% to $2.6 million from $3.4 million [4] - Licenses revenue fell by 29% to $1.8 million from $2.5 million [4] Strategic Developments - The company signed its fourth Strategic Platform License (SPL) agreement of the year with Moonlight Bio, bringing the total number of SPL agreements to 32 [3][6] - MaxCyte is committed to investing in SeQure Dx and enhancing its product offerings while ensuring commercial discipline for sustainable growth [3][6] Key Metrics - The installed base of instruments increased to 830 as of September 30, 2025, up from 739 in the previous year [4] - Core revenue generated by SPL clients accounted for 53% of total core revenue, consistent with the previous year [4]

Core Insights - MaxCyte, Inc. announced preliminary results for Q3 2025, reporting total revenue of $6.8 million, a 16% decrease from $8.2 million in Q3 2024 [1][7] - The company reiterated its 2025 revenue guidance, expecting total cash, cash equivalents, and investments to be between $152 million and $155 million by year-end [10][15] Financial Performance - Core revenue for Q3 2025 was $6.4 million, down 21% from $8.1 million in Q3 2024 [6][7] - Revenue from Strategic Platform License (SPL) Program-related activities was $0.4 million, a significant increase of 1,663% compared to $24,000 in the same quarter of the previous year [6][7] - The gross margin for Q3 2025 was $5.2 million, representing a 77% gross margin, while the non-GAAP adjusted gross margin was 81% when excluding SPL Program-related revenue [7][21] Revenue Breakdown - Revenue sources for Q3 2025 included: - Instruments: $1.4 million (down 22%) - PAs and consumables: $2.6 million (down 25%) - Licenses: $1.8 million (down 29%) - Assay services: $248,000 (new revenue source) - Other: $402,000 (down 3%) [6][7] Client and Market Activity - The company added one new SPL client, Moonlight Bio, in October 2025, bringing the total number of SPL agreements to 32 [7] - The installed base of instruments increased to 830 units, up from 739 units in the previous year [9] Upcoming Events - Management will present at the Stifel Healthcare Conference on November 11, 2025, and the Stephens Investment Conference on November 19, 2025 [1][16]

Core Viewpoint - MaxCyte, Inc. is set to release its financial results for Q2 2025 on August 6, 2025, after the U.S. market closes, followed by a conference call to discuss these results [1]. Group 1: Financial Results Announcement - The financial results for the second quarter of 2025 will be announced after the U.S. market closes on August 6, 2025 [1]. - A conference call will be hosted by company management at 4:30 p.m. Eastern Time to discuss the financial results [1]. Group 2: Conference Call Details - Investors interested in the conference call must register online, with a recommendation to register at least a day in advance [2]. - A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website [2]. Group 3: Company Overview - MaxCyte is a leading cell-engineering company focused on advancing the discovery, development, and commercialization of next-generation cell therapies [3]. - The company utilizes Flow Electroporation technology and SeQure DX™ gene editing risk assessment services to enable precise and scalable cell engineering [3]. - With over 25 years of experience, MaxCyte aims to shape the future of medicine by empowering researchers globally to develop safe and effective treatments [3].